Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

US Patent 9518064 · Granted Dec 13, 2016

Estimated economic value: $667,908,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosi2025
Substituted carbazole compounds2025
Heterocyclic mitochondrial activity inhibitors and uses thereof2025
Substituted indole and indazole compounds2024
Apelin receptor agonists and methods of use2024
Inhibitors of protein tyrosine phosphatase, compositions, and methods of use2024
Methods of treating kidney failure, and/or improving or stablizing renal functio2024
Treatment of fibrosis, cardiovascular disease and heart failure with modified re2024
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2024
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2024
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2024
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2024